Pearls, Pitfalls and Challenges in Toxicities Associated with Immotherapy and Targeted Therapies: What We Know Now
With the increasing use of cancer immunotherapies for a variety of cancers, including lung cancer, there has been a parallel increase in the toxicity profile across organ systems. The lungs are not the most frequent organ system adversely impacted by cancer immunotherapy, but toxicity to this organ system may be severe and potentially life-threatening. Practitioners must have a working knowledge that permits early identification of patients at risk for lung injury associated with cancer immunotherapies. Furthermore, knowledge of best practices regarding management and drug rechallenge in this group of patients is critical to successful patient outcomes.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Recognize patients at risk for immunotherapy-related lung toxicity.
- Recognize early clinical signs and symptoms of immunotherapy-related lung injury.
- Understand how to diagnose and manage patients with immunotherapy-related lung disease.
- Understand drug rechallenge strategies: Who? When? How?.
- Vickie Shannon, MD
- Abdul Rafeh Naqash, MB
- Karthik Suresh, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.